Orna Therapeutics
Orna Therapeutics, a pioneering biotechnology company based in the United States, is at the forefront of RNA therapeutics. Founded in 2020, the company has rapidly established itself as a leader in the development of innovative circular RNA (circRNA) technologies, which offer unique advantages in gene expression and therapeutic applications. With its headquarters in Cambridge, Massachusetts, Orna Therapeutics focuses on creating transformative therapies for a range of diseases, including cancer and genetic disorders. The company’s proprietary circRNA platform distinguishes it from traditional RNA approaches, enabling enhanced stability and efficacy. Orna Therapeutics has garnered attention for its commitment to advancing the field of RNA-based medicine, positioning itself as a key player in the biotechnology industry. Its groundbreaking research and development efforts continue to pave the way for novel treatment options, making significant strides in the quest for effective therapies.
DitchCarbon Score
How does Orna Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orna Therapeutics's score of 3 is lower than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Orna Therapeutics's reported carbon emissions
Orna Therapeutics, headquartered in the US, currently does not have publicly available carbon emissions data for recent years, as indicated by the absence of specific figures. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of data suggests that Orna Therapeutics may still be in the early stages of formalising its climate commitments or reporting its emissions. In the context of the biotechnology industry, companies are increasingly expected to establish clear sustainability goals and transparent reporting practices to address climate change effectively.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orna Therapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
